Receptivity to Taboka and Camel Snus in a U.S. test market
Open Access
- 29 June 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 11 (10), 1154-1159
- https://doi.org/10.1093/ntr/ntp113
Abstract
The two largest U.S. cigarette manufacturers introduced Swedish-style low-nitrosamine smokeless tobacco (snus) to several U.S. test markets in summer 2006. Since then, snus brands and test markets have proliferated. This article assesses consumer response by analyzing data from the 2006 and 2007 Indiana Adult Tobacco Survey (IATS), a statewide telephone survey of 3,544 adults. During those years, the IATS included questions on awareness and trial of Camel Snus and Taboka. Analyses examined rates and predictors of awareness and trial statewide, and within the central Indiana test market. Nineteen percent of Indiana adults were aware of either Taboka or Camel Snus in 2006 and 2007. Estimates are larger (29%) for central Indiana and larger still (70%) for central Indiana smokers. Trial of snus, however, was very low (1.5% statewide), except among male smokers in central Indiana, 20% of whom are estimated to have tried it. Multivariate analyses showed that trial was more likely among men than women (odds ratio [OR] 13.85), residents of central Indiana than those farther from Indianapolis (OR 2.96), recipients than nonrecipients of tobacco promotions (OR 6.08), and those believing that smokeless tobacco is less harmful than cigarettes compared with those who believe it is equally or more harmful (OR 3.86). Results from this study suggest substantial initial interest in the new products among male smokers in this test market, especially those who receive promotional mailings from tobacco companies, which often include coupons for free or discounted products.Keywords
This publication has 14 references indexed in Scilit:
- The Strategic Dialogue on Tobacco Harm Reduction: a vision and blueprint for action in the USTobacco Control, 2009
- Exposure to nicotine and a tobacco-specific carcinogen increase with duration of use of smokeless tobaccoTobacco Control, 2008
- Epidemiologic Perspectives on Smokeless Tobacco Marketing and Population HarmAmerican Journal of Preventive Medicine, 2007
- Smokers' beliefs about the relative safety of other tobacco products: Findings from the ITC CollaborationNicotine & Tobacco Research, 2007
- Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort studyThe Lancet, 2007
- Trends in Smokeless Tobacco Use Among Adults and Adolescents in the United StatesAmerican Journal of Public Health, 2006
- “Not safe” is not enough: smokers have a right to know more than there is no safe tobacco productTobacco Control, 2005
- The Relative Risks of a Low-Nitrosamine Smokeless Tobacco Product Compared with Smoking Cigarettes: Estimates of a Panel of ExpertsCancer Epidemiology, Biomarkers & Prevention, 2004
- European Union policy on smokeless tobacco: a statement in favour of evidence based regulation for public healthTobacco Control, 2003
- Effect of smokeless tobacco (snus) on smoking and public health in SwedenTobacco Control, 2003